Cost-Effectiveness of an Adjuvanted Hepatitis B Vaccine (HEPLISAV-B) in Patients With Inflammatory Bowel Disease

BACKGROUND: Compare the cost-effectiveness of 2 recombinant hepatitis B virus (HBV) vaccines in patients with inflammatory bowel disease (IBD). METHODS: Markov models were developed for 2 IBD cohorts: (1) 40-year-old patients prior to starting IBD treatment and (2) 40-year-old patients already recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Corral, Juan E, Kwon, Joshua Y, Caldera, Freddy, Pungpapong, Surakit, Spaulding, Aaron C, Borah, Bijan J, Moriarty, James P, Farraye, Francis A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802290/
https://www.ncbi.nlm.nih.gov/pubmed/36777070
http://dx.doi.org/10.1093/crocol/otaa090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802290/
https://www.ncbi.nlm.nih.gov/pubmed/36777070
http://dx.doi.org/10.1093/crocol/otaa090

Ejemplares similares